Spero Therapeutics, Inc. Net Fee Amt
Spero Therapeutics, Inc. (SPRO) had Net Fee Amt of $7.98 thousand as of 2026-08-28, per its S-3 filed 2026-08-28.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-08-28
- 2026-08-28: Net Fee Amt $7.98K.
- 2026-06-23: Net Fee Amt $4.02K.
| Period end | Net Fee Amt |
|---|---|
| 2026-08-28 | $7.98K S-3 · filed 2026-08-28 |
| 2026-06-23 | $4.02K S-8 · filed 2026-06-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |